Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancerE Vrdoljak, N Marschner, C Zielinski, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2018
Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trialM Ignatiadis, S Litière, F Rothe, et al.
British Journal of Cancer|July 23, 2013
International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancerS Wheelwright, A-S Darlington, D Fitzsimmons, et al.
Breast (Edinburgh, Scotland)|October 8, 2013
Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trialF Valet, P de Cremoux, F Spyratos, et al.
ESMO Open|May 4, 2024
Incidence and outcome of brain and/or leptomeningeal metastases in HER2-low metastatic breast cancer in the French ESME cohortN Epaillard, A Lusque, W Jacot, et al.
ESMO Open|September 4, 2024
Adequate assessment yields appropriate care-the role of geriatric assessment and management in older adults with cancer: a position paper from the ESMO/SIOG Cancer in the Elderly Working GroupK P Loh, G Liposits, S P Arora, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2018
Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patientsE Jacquet, A Lardy-Cléaud, B Pistilli, et al.
ESMO Open|September 18, 2025
Real-world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR-positive/HER2-negative metastatic breast cancer in the ESME-MBC cohortR Varnier, D Pérol, W Jacot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2024
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PETA Gennari, E Brain, A De Censi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45V Bjelic-Radisic, F Cardoso, D Cameron, et al.
Pageof 11